Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model. - Wikidata - wikimedia - TriplyDB

Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model.

Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model.

http://www.wikidata.org/entity/Q33625341

about

The Cosmc connection to the Tn antigen in cancer.The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.

P2860

Q38197051-BA700FC5-CBF8-4BE3-9EF5-17FD50D809D1 Q39274501-7348205A-ED5F-444F-82EC-CF00AF43DA41

P2860

Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model.

http://www.wikidata.org/entity/Q33625341

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Biodistribution of HuCC49Delta ...... rectal cancer xenograft model.

@ast

Biodistribution of HuCC49Delta ...... rectal cancer xenograft model.

@en

type

label

Biodistribution of HuCC49Delta ...... rectal cancer xenograft model.

@ast

Biodistribution of HuCC49Delta ...... rectal cancer xenograft model.

@en

prefLabel

Biodistribution of HuCC49Delta ...... rectal cancer xenograft model.

@ast

Biodistribution of HuCC49Delta ...... rectal cancer xenograft model.

@en

P1433

Q33625341-E57D30E2-DDC1-494F-9E89-EA7D8D490D42

P1476

Q33625341-8571A700-C938-4403-9D55-44B02AF3594C

P2093

Q33625341-231F85AC-EBE9-4120-BC7A-505722434E9D

Q33625341-3A69CF4F-6A6E-4AB1-8E24-F66CC470C4DF

Q33625341-EDEABEE6-27C4-4920-BE01-14CF5560ABCE

P2860

Q33625341-0635FEFB-6872-47D8-AA86-FE668B6943A4

Q33625341-07577A63-CDBF-47E3-A934-6B9C7F98134D

Q33625341-16FB03E1-65F7-4E45-A726-0346D42F9BB1

Q33625341-196C9599-12D0-47B1-9F0C-34725AB7BA9E

Q33625341-25001297-5EE3-4B18-A470-133271A0E5BE

Q33625341-256A37BC-C9BE-41FA-B09D-D6C8654CAAF3

Q33625341-2E1F4241-8544-43A2-BD57-A38685C9DB47

Q33625341-5F6688B1-1B78-4F54-8117-95A49BA82874

Q33625341-69ABE0E3-C2B4-4F8E-9DA2-0F885D5D5DFB

Q33625341-72D60B89-0501-4D31-B32F-EF98E958562B

P304

Q33625341-ACA9C977-6D95-4159-8E8E-81D5B95BF7B5

P31

Q33625341-FC6A7942-F256-44F6-95C0-54330915458C

P356

Q33625341-40BE7626-F2C5-4F4F-86FE-C4BEDAF836A2

P407

Q33625341-349814B4-06B2-4F6C-A981-9FE251A89CE1

P433

Q33625341-9D825789-06A2-4239-892A-C9BB563EB11E

P478

Q33625341-B8E28E56-8985-4233-B0EA-C25085DCB765

P577

Q33625341-C8846349-13FD-4A94-A583-92B4B4FB6343

P5875

Q33625341-02FA6549-3995-4AE1-826E-D87C0201F765

P698

Q33625341-6BEC5D3F-DBF5-4148-96E1-1469702DD0B4

P921

Q33625341-0AFBB84B-7783-4427-88E4-4ACCAC3A876E

Q33625341-9405A86D-06E9-4236-88B9-E588733792CA

P932

Q33625341-60B27781-ACD1-43D2-8E38-EF38F0658132

P356

J.IJPHARM.2009.11.020

P1433

International Journal of Pharmaceutics

P1476

Biodistribution of HuCC49Delta ...... rectal cancer xenograft model.

@en

P2093

Duxin Sun

http://www.w3.org/2001/XMLSchema#string

Lanyan Fang

http://www.w3.org/2001/XMLSchema#string

Yanke Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)

Antibody-directed enzyme prodrug therapy (ADEPT): a review.

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Advances in antibody-directed enzyme prodrug therapy.

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug

Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates

Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.

Antibody-toxin hybrids: a clinical review of their use.

Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.

P304

208-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJPHARM.2009.11.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

386

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40037281

http://www.w3.org/2001/XMLSchema#string

P698

19944136

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2815147

http://www.w3.org/2001/XMLSchema#string